ES2791525T3 - Derivados de aminopirimidina novedosos - Google Patents

Derivados de aminopirimidina novedosos Download PDF

Info

Publication number
ES2791525T3
ES2791525T3 ES17191467T ES17191467T ES2791525T3 ES 2791525 T3 ES2791525 T3 ES 2791525T3 ES 17191467 T ES17191467 T ES 17191467T ES 17191467 T ES17191467 T ES 17191467T ES 2791525 T3 ES2791525 T3 ES 2791525T3
Authority
ES
Spain
Prior art keywords
disease
mmol
int
compound
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17191467T
Other languages
English (en)
Spanish (es)
Inventor
Daniela Angst
François Gessier
Anna Vulpetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2791525T3 publication Critical patent/ES2791525T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES17191467T 2013-11-29 2014-11-28 Derivados de aminopirimidina novedosos Active ES2791525T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13195081 2013-11-29

Publications (1)

Publication Number Publication Date
ES2791525T3 true ES2791525T3 (es) 2020-11-04

Family

ID=49674216

Family Applications (4)

Application Number Title Priority Date Filing Date
ES17191467T Active ES2791525T3 (es) 2013-11-29 2014-11-28 Derivados de aminopirimidina novedosos
ES14821285.5T Active ES2655527T3 (es) 2013-11-29 2014-11-28 Derivados novedosos de amino pirimidina
ES23161775T Active ES3040769T3 (en) 2013-11-29 2014-11-28 Method of preparing amino pyrimidine derivatives
ES20158961T Active ES2947770T3 (es) 2013-11-29 2014-11-28 Derivados de aminopirimidina novedosos

Family Applications After (3)

Application Number Title Priority Date Filing Date
ES14821285.5T Active ES2655527T3 (es) 2013-11-29 2014-11-28 Derivados novedosos de amino pirimidina
ES23161775T Active ES3040769T3 (en) 2013-11-29 2014-11-28 Method of preparing amino pyrimidine derivatives
ES20158961T Active ES2947770T3 (es) 2013-11-29 2014-11-28 Derivados de aminopirimidina novedosos

Country Status (42)

Country Link
US (6) US9512084B2 (enExample)
EP (5) EP3689865B1 (enExample)
JP (2) JP6342495B2 (enExample)
KR (2) KR102380539B1 (enExample)
CN (2) CN110172056B (enExample)
AP (1) AP2016009158A0 (enExample)
AR (1) AR098549A1 (enExample)
AU (1) AU2014356069B2 (enExample)
BR (1) BR112016010397B1 (enExample)
CA (1) CA2926908C (enExample)
CL (1) CL2016001055A1 (enExample)
CR (1) CR20160244A (enExample)
CU (1) CU24384B1 (enExample)
CY (3) CY1119705T1 (enExample)
DK (3) DK3299368T3 (enExample)
EA (1) EA031218B1 (enExample)
EC (1) ECSP16054826A (enExample)
ES (4) ES2791525T3 (enExample)
FI (1) FI3689865T3 (enExample)
HR (3) HRP20230585T1 (enExample)
HU (3) HUE037588T2 (enExample)
IL (1) IL244943B (enExample)
JO (1) JO3314B1 (enExample)
LT (3) LT3074386T (enExample)
MA (1) MA39055B1 (enExample)
MX (1) MX367911B (enExample)
MY (2) MY179059A (enExample)
NO (1) NO3074386T3 (enExample)
NZ (1) NZ718835A (enExample)
PE (1) PE20160869A1 (enExample)
PH (1) PH12016500791B1 (enExample)
PL (3) PL3074386T3 (enExample)
PT (3) PT3689865T (enExample)
RS (3) RS64275B1 (enExample)
SI (3) SI3689865T1 (enExample)
SV (1) SV2016005206A (enExample)
TN (1) TN2016000128A1 (enExample)
TW (1) TWI652261B (enExample)
UA (1) UA117256C2 (enExample)
UY (1) UY35858A (enExample)
WO (1) WO2015079417A1 (enExample)
ZA (1) ZA201602275B (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
SI3888674T1 (sl) 2014-04-07 2024-08-30 Novartis Ag Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
RU2020117196A (ru) 2014-08-19 2020-10-15 Новартис Аг Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
JP6839074B2 (ja) 2014-09-17 2021-03-03 ノバルティス アーゲー 養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
UY36351A (es) 2014-10-14 2016-06-01 Novartis Ag Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3280795B1 (en) * 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
ES2986067T3 (es) 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
WO2017149515A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
MY200337A (en) 2016-10-07 2023-12-20 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
JP7227131B2 (ja) 2016-12-03 2023-02-21 ジュノー セラピューティクス インコーポレイテッド Ｃａｒ－ｔ細胞の投薬を決定するための方法
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
KR20200054160A (ko) 2017-06-02 2020-05-19 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
KR20200074997A (ko) 2017-11-01 2020-06-25 주노 쎄러퓨티크스 인코퍼레이티드 B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102845789B1 (ko) 2017-11-01 2025-08-14 주노 쎄러퓨티크스 인코퍼레이티드 B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
TWI694995B (zh) * 2017-11-06 2020-06-01 美商美國禮來大藥廠 Btk抑制劑化合物
CN111989106A (zh) 2017-12-01 2020-11-24 朱诺治疗学股份有限公司 基因工程化细胞的给药和调节方法
CN108069911A (zh) * 2017-12-14 2018-05-25 中国药科大学 6－氨基－2－苯基嘧啶类化合物、制备方法和医药用途
WO2019118937A1 (en) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
JP7438988B2 (ja) 2018-06-13 2024-02-27 ノバルティス アーゲー Ｂｃｍａキメラ抗原受容体及びその使用
CN112424207B (zh) 2018-07-25 2024-03-19 诺华股份有限公司 Nlrp3炎性小体抑制剂
EP3844149A1 (en) 2018-08-29 2021-07-07 Acerta Pharma B.V. Processes for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}n-(pyridin-2-yl)-benzamide
MX2021005024A (es) 2018-11-01 2021-07-21 Juno Therapeutics Inc Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
CA3116413A1 (en) 2018-11-01 2020-05-07 Juno Therapeutics, Inc. Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
SG11202105084VA (en) 2018-11-16 2021-06-29 Juno Therapeutics Inc Methods of dosing engineered t cells for the treatment of b cell malignancies
FI3886875T3 (fi) 2018-11-30 2024-07-23 Juno Therapeutics Inc Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
CN113365660A (zh) 2019-01-29 2021-09-07 朱诺治疗学股份有限公司 对受体酪氨酸激酶样孤儿受体1(ror1)具特异性的抗体及嵌合抗原受体
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
WO2020234780A1 (en) 2019-05-23 2020-11-26 Novartis Ag Methods of treating asthma using a bruton's tyrosine kinase inhibitor
ES3039974T3 (en) * 2019-05-23 2025-10-28 Novartis Ag A bruton's tyrosine kinase inhibitor for use in the treatment of chronic spontaneous urticaria
EP3972603B1 (en) * 2019-05-23 2024-09-04 Novartis AG Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor
CN121471151A (zh) 2019-05-23 2026-02-06 诺华股份有限公司 Btk抑制剂的晶型
JP7646671B2 (ja) * 2019-12-23 2025-03-17 バイオジェン・エムエイ・インコーポレイテッド Ｂｔｋ阻害剤
BR112022020333A2 (pt) 2020-04-10 2022-11-22 Juno Therapeutics Inc Métodos e usos relacionados à terapia celular projetada com um receptor de antígeno quimérico que alveja o antígeno de maturação de células b
CN116209444A (zh) * 2020-08-14 2023-06-02 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物的晶型及其制备方法
EP4196478A1 (en) 2020-08-14 2023-06-21 Novartis AG Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof
MX2023008671A (es) 2021-01-26 2023-09-25 Novartis Ag Composicion farmaceutica.
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
EP4395779A1 (en) 2021-09-03 2024-07-10 Novartis AG Lou064 for treating multiple sclerosis
WO2023111802A1 (en) 2021-12-14 2023-06-22 Novartis Ag Methods of treatment using lou064
TW202342048A (zh) 2022-02-28 2023-11-01 瑞士商諾華公司 使用ｌｏｕ０６４治療化膿性汗腺炎之方法
US20250381272A1 (en) 2022-06-22 2025-12-18 Juno Therapeutics, Inc. Treatment methods for second line therapy of cd19-targeted car t cells
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
KR20250047766A (ko) 2022-08-05 2025-04-04 주노 쎄러퓨티크스 인코퍼레이티드 Gprc5d 및 bcma에 특이적인 키메라 항원 수용체
WO2024069507A1 (en) 2022-09-30 2024-04-04 Novartis Ag Synthesis methods and intermediates for the production of remibrutinib
CN120712102A (zh) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
AU2024345255A1 (en) * 2023-09-22 2026-03-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Heteroaryl compound, and preparation method therefor and use thereof in medicine
CN117024354B (zh) * 2023-10-08 2023-12-08 天津凯莱英制药有限公司 瑞米布替尼的制备方法
US20250243170A1 (en) 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity
WO2025210469A2 (en) 2024-04-02 2025-10-09 Novartis Ag Process of preparing remibrutinib substantially free of nitrosamine impurity
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
CA2426508A1 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
ES2332770T3 (es) 2000-11-07 2010-02-12 Novartis Ag Derivados de indolilmaleimida como inhibidores de la proteina quinasa c.
AR036053A1 (es) 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
EP2322203A3 (en) 2002-10-29 2011-07-27 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP1578411A4 (en) 2002-12-09 2007-05-02 Univ Texas PROCESS FOR THE SELECTIVE INHIBITION OF JANUS TYROSINE KINASE3 (JAK3)
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
WO2005000833A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
DK1704145T3 (da) 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
MX2007011041A (es) 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
EP2270200A3 (en) 2006-09-11 2011-07-13 CGI Pharmaceuticals, Inc. Kinase inhibitors, and methods of using and identifying kinase inhibitors
AR063946A1 (es) * 2006-09-11 2009-03-04 Cgi Pharmaceuticals Inc Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
US8232085B2 (en) 2007-03-14 2012-07-31 Bionsil S.R.L. Isoform of bruton's tyrosine kinase (BTK) protein
US8426424B2 (en) 2008-05-06 2013-04-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
AU2009265813B2 (en) 2008-07-02 2014-04-10 F. Hoffmann-La Roche Ag Novel phenylpyrazinones as kinase inhibitors
CN105362277A (zh) 2008-07-16 2016-03-02 药品循环有限公司 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂
US20100261776A1 (en) 2008-11-07 2010-10-14 The Research Foundation Of State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CA2748414A1 (en) 2009-04-24 2010-10-28 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
BR112012021453A2 (pt) * 2010-02-26 2017-02-21 Boehringer Ingelheim Int tienopirimidina, sua composição farmacêutica e seu uso
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
WO2012135801A1 (en) 2011-04-01 2012-10-04 University Of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
PL2710007T3 (pl) 2011-05-17 2020-06-01 The Regents Of The University Of California Inhibitory kinazy
LT2718270T (lt) 2011-06-10 2022-08-10 Merck Patent Gmbh Pirimidino ir piridino junginių, turinčių btk inhibitorinį aktyvumą, kompozicijos ir gamybos būdai
MX2014000130A (es) 2011-06-28 2014-05-01 Pharmacyclics Inc Procedimientos y composiciones para la inhibicion de resorcion osea.
WO2013008095A1 (en) 2011-07-08 2013-01-17 Novartis Ag Novel pyrrolo pyrimidine derivatives
EP3778896A1 (en) 2011-08-09 2021-02-17 Fred Hutchinson Cancer Research Center Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
KR20250086805A (ko) 2011-10-19 2025-06-13 파마싸이클릭스 엘엘씨 브루톤 티로신 인산화효소(btk)의 억제제의 용도
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
US8742098B2 (en) 2011-12-09 2014-06-03 Hoffmann-La Roche Inc. Inhibitors of Bruton's tyrosine kinase
US20150011751A1 (en) 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
JP6182593B2 (ja) 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JP6348492B2 (ja) 2012-08-10 2018-06-27 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤としてのヘテロ芳香族化合物
EP2903972B1 (en) 2012-10-04 2019-12-04 University of Utah Research Foundation Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives

Also Published As

Publication number Publication date
JP6667573B2 (ja) 2020-03-18
AP2016009158A0 (en) 2016-04-30
EP3689865B1 (en) 2023-03-29
RS56657B1 (sr) 2018-03-30
AU2014356069A1 (en) 2016-05-05
ZA201602275B (en) 2017-08-30
CU24384B1 (es) 2019-03-04
PT3074386T (pt) 2017-11-15
HRP20230585T1 (hr) 2023-09-01
KR102421388B1 (ko) 2022-07-18
US20230312483A1 (en) 2023-10-05
MA39055A1 (fr) 2018-02-28
DK3074386T3 (en) 2018-01-22
EP3074386A1 (en) 2016-10-05
IL244943B (en) 2020-04-30
ES3040769T3 (en) 2025-11-04
PH12016500791A1 (en) 2016-06-13
MY179059A (en) 2020-10-26
IL244943A0 (en) 2016-05-31
DK3299368T3 (da) 2020-05-25
CA2926908C (en) 2021-10-26
MY191381A (en) 2022-06-22
US20200010426A1 (en) 2020-01-09
KR20160088877A (ko) 2016-07-26
PL3074386T3 (pl) 2018-03-30
SI3689865T1 (sl) 2023-07-31
CU20160078A7 (es) 2016-09-30
DK3689865T3 (en) 2023-06-19
HUE037588T2 (hu) 2018-09-28
UY35858A (es) 2015-06-30
AU2014356069B2 (en) 2017-06-15
US20180251432A1 (en) 2018-09-06
PT3689865T (pt) 2023-06-16
CN105683181A (zh) 2016-06-15
EP4606377A3 (en) 2025-11-26
MX2016006908A (es) 2016-08-17
US11673868B2 (en) 2023-06-13
JP2016538313A (ja) 2016-12-08
CA2926908A1 (en) 2015-06-04
EP3074386B1 (en) 2017-10-11
PL3689865T3 (pl) 2023-07-31
US20160235746A1 (en) 2016-08-18
ECSP16054826A (es) 2017-10-31
LT3299368T (lt) 2020-05-25
CY1126056T1 (el) 2023-11-15
FI3689865T3 (fi) 2023-06-12
JP2018141005A (ja) 2018-09-13
CN110172056B (zh) 2022-04-19
HRP20171999T1 (hr) 2018-02-09
NO3074386T3 (enExample) 2018-03-10
EA031218B1 (ru) 2018-12-28
PE20160869A1 (es) 2016-09-08
EP4219478A1 (en) 2023-08-02
CY1119705T1 (el) 2018-06-27
CR20160244A (es) 2016-07-29
LT3689865T (lt) 2023-07-10
KR20220044370A (ko) 2022-04-07
MA39055B1 (fr) 2018-10-31
HRP20200775T1 (hr) 2020-07-24
JP6342495B2 (ja) 2018-06-13
EP3299368A1 (en) 2018-03-28
WO2015079417A1 (en) 2015-06-04
TWI652261B (zh) 2019-03-01
EA201691125A1 (ru) 2016-09-30
HUE049794T2 (hu) 2020-10-28
SI3074386T1 (en) 2018-02-28
CN110172056A (zh) 2019-08-27
BR112016010397A8 (pt) 2020-04-22
US11180460B2 (en) 2021-11-23
EP4219478B1 (en) 2025-06-11
NZ718835A (en) 2021-12-24
HK1223368A1 (en) 2017-07-28
TW201609666A (zh) 2016-03-16
EP3689865A1 (en) 2020-08-05
JO3314B1 (ar) 2019-03-13
RS64275B1 (sr) 2023-07-31
EP4606377A2 (en) 2025-08-27
ES2655527T3 (es) 2018-02-20
HK1252317A1 (en) 2019-05-24
US20220041561A1 (en) 2022-02-10
ES2947770T3 (es) 2023-08-18
CY1122924T1 (el) 2021-10-29
SI3299368T1 (sl) 2020-07-31
SV2016005206A (es) 2016-11-21
PT3299368T (pt) 2020-05-28
TN2016000128A1 (en) 2017-10-06
US9512084B2 (en) 2016-12-06
EP3299368B1 (en) 2020-02-26
KR102380539B1 (ko) 2022-03-29
US10457647B2 (en) 2019-10-29
BR112016010397B1 (pt) 2023-04-11
LT3074386T (lt) 2017-12-27
HUE062248T2 (hu) 2023-10-28
CL2016001055A1 (es) 2016-10-28
PH12016500791B1 (en) 2016-06-13
UA117256C2 (uk) 2018-07-10
MX367911B (es) 2019-09-11
AR098549A1 (es) 2016-06-01
US20150152068A1 (en) 2015-06-04
PL3299368T3 (pl) 2020-08-10
CN105683181B (zh) 2019-04-23
RS60251B1 (sr) 2020-06-30

Similar Documents

Publication Publication Date Title
ES2791525T3 (es) Derivados de aminopirimidina novedosos
HK40127042A (en) Novel amino pyrimidine derivatives
HK40089302B (en) Method of preparing amino pyrimidine derivatives
HK40024076B (en) Novel amino pyrimidine derivatives
HK40024076A (en) Novel amino pyrimidine derivatives
HK1252317B (en) Novel amino pyrimidine derivatives
HK1223368B (en) Novel amino pyrimidine derivatives